ArticleRSC advances2026
Development of bioactive SF/HAp/ZnO scaffolds incorporating succinic acid with potential bone regeneration capabilities.
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The challenges associated with using autografts for repairing bone defects have increased the demand for synthetic bone graft substitutes that can offer both structural support and biological activity. In this research, we developed a composite scaffold made of silk fibroin, hydroxyapatite, and ZnO (SF/HAp/ZnO), incorporating succinic acid (SA) as a functional additive to improve the physicochemical and biological properties of the scaffold. The morphology of the synthesized scaffold was confirmed by FESEM analysis, and a rougher morphology than pure SF was observed in the scaffolds. The study revealed that the scaffold displayed slow degradation (4.84% after 21 days in S4) and high swelling
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.